Methodology, Applications and Advancements of Car-T Cell Therapy in Malignancies

Ganne Goutham Sai*1, Dusanapudi Swathi2, Dorepalli Lalitha2, Ganjala Tulasi2

1V.V.Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, near Railway Station, Gudlavalleru, Andhra Pradesh 521356, India
2Sri Vasavi Institute of Pharmaceutical Sciences, Pedatadepalli, Tadepalligudem - 534 101, West Godavari Dist., Andhra Pradesh, India

Article History:
Received on: 08 Mar 2024
Revised on: 20 Mar 2024
Accepted on: 25 Mar 2024

Abstract
Despite significant advancements in cancer therapy, traditional treatments like radiation, chemotherapy, and surgery often fall short, underscoring the need for innovative approaches like activated cell therapy. Chimeric antigen receptor T cells (CAR-T cells) represent a pioneering form of this therapy, targeting cancer with modified T lymphocytes. While CAR-T cell therapy has shown high effectiveness in hematological malignancies, its success in solid tumors has been limited due to challenges such as proliferation, stability, trafficking, and tumor environment navigation. Overcoming these hurdles is crucial for enhancing the therapy’s efficacy against solid tumors. The success rate of CAR-T cell therapy can reach up to 90% in leukemia patients, illustrating its potential. However, its application is still nascent, with much to learn about its long-term effectiveness and safety. This study provides an in-depth review of CAR-T cell therapy’s accomplishments and limitations in cancer treatment and explores the potential of combining CAR-T cell therapy with other treatments.

INTRODUCTION
Recent years have seen a rapid development of cancer treatment techniques, with immunotherapy in particular emerging as one of the most quickly evolving therapeutic possibilities. Immunotherapy has progressively taken the lead as the primary therapeutic choice for malignant hematological disorders, and CAR-T cell immunotherapy has shown remarkable outcomes in the treatment of cancer [1]. All of the newest developments, including CB-010 therapy, to Kymriah and Yescarta, which were the first to be authorized by the FDA in August and October 2017 to treat leukemia and lymphoma, are crucial
in the treatment of malignant tumors, especially in situations of recurrence and resistant malignancies [2]. The spacer is required to join the transmembrane segment—an alpha helix found in the cell membrane—to the antigen recognition area. This segment connects the intracellular cytoplasmic domain to the extracellular antigen binding domain. Comprising of activation and co-stimulatory domains, the intracellular domain of the CAR represents its functional terminal [3]. In the cytoplasmic domain of CD3, ITAMs (immunoreceptor tyrosine-based activation motifs) are the most prevalent intracellular domain element. Specifically, the T cell receives an activation signal when an antigen binds with an antigen recognition domain. In addition, co-stimulatory signaling is necessary for T cell activation to be successful [4].

Figure 1: CAR T cell

STRUCTURE OF CAR-T CELL

The three primary parts of CAR are the intracellular, trans membrane, and extracellular domains. The signal peptide, a region that recognizes the tumor-associated antigen (TAA), consists of a spacer and an extracellular domain [5]. The variable part of the heavy (VH) and light (VL) chains of an antibody connected by a flexible linker is similar to the single-chain variable fragment (scFv) region that characterises the extracellular domain. The trans membrane section of the cell membrane, which is an alpha helix that connects the intracellular cytoplasmic domain to the extracellular antigen-binding domain, requires the spacer in order to connect the antigen recognition area to it [6]. The functional terminal of the CAR, which typically contains activation and co-stimulatory domains, is known as the intracellular domain. Within the cytoplasmic domain of CD3, the most prevalent intracellular domain component is called an ITAMS (immunoreceptor tyrosine-based activation motifs). Specifically, an activation signal is given to the T cell when an antigen binds with an antigen identification domain. Furthermore, co-stimulatory signaling is necessary for T cell activation [7].

Figure 2: Structure of CAR T cell [8]

Fifth unique versions of CAR T cells have been identified based on the intracellular domain's shape. In order to maximize the intracellular domain of CAR structures, most CAR engineering efforts have often been focused on comprehending the consequences of CAR co-stimulation [9].

First generation CAR-T cell

When CARs were first developed, all that was needed for activation of T cells was the Fc receptor-chain (FCR), or CD3 chain from the CD3 TCR, coupled to an exogenous scFv. Additionally, prolonged cytokine production or effective T cell responses cannot be achieved by just talking with these regions [10]. Consequently, this generation of CARs was discontinued due to insufficient anticancer efficaciousness in vivo, strength, and signaling capability [11].

Second generation CAR-T cell

Early in the new millennium, second-generation CARs were created with the CD3ζ intracellular domain in sequence with a single co-stimulatory domain, such as CD 28 or 4-1BB (CD137), as the
significance of co-stimulation for the maintenance of CAR-T cell therapy became apparent. Clinical investigations have demonstrated that these intracellular signalling domains provide robust anti-cancer activity in patients with non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia, and they also enhance T-cell persistence, secretion of cytokines, and anti-cancer efficiency in preliminary models [12].

Third generation CAR-T cell

Multiple co-stimulatory domains, such as CD28-41BB or CD28-OX40, were combined to create third-generation CARs, which increased the potency of CAR-T cells by producing more cytokines, having an anticancer effect, and promoting T-cell proliferation [13]. Furthermore, in comparison with second-generation CARs, several preclinical trials using third-generation CARs have shown to improve effectiveness, proliferation, and cytokine production in the clinic. On the other hand, data about whether patients respond better to second- or third-generation CAR T-cells is inconsistent [14].

Fourth generation CAR-T cell

Through the use of more recent, transgenic genetic changes, including transgenes for cytokine release and other co-stimulatory ligands, a fourth-generation kind of T cell-based immunotherapy was developed. Consequently, CAR-T cell activity and proliferation are enhanced by immunostimulatory cytokines like IL-2, which also increase the cells’ resilience to the immunosuppressive tumor microenvironment. These cytokines also stimulate and attract the innate immune system to the site of the tumor [15].

MECHANISM OF CAR-T CELL THERAPY

To express rebuilding of the CAR receptor for tumor-specific antigens, autologous T-cells are genetically modified as part of this therapy [16]. CARs are proteins that fusion together made up of the intracellular signaling domains of one or more T-cell receptors and the antigen-recognition portion of an antibody that is monoclonal. CAR-T cell treatment typically takes a few weeks to complete [17]. After removing autologous T-cells from the blood by leukapheresis, the cells are genetically modified ex vivo using both viral and non-viral transfection techniques. Ultimately, the patient receives another infusion of CAR T-cells [18].

ADDITIONS OF CAR-T CELL THERAPY

For patients with advanced CLL, CAR-T cell treatment presents a challenge since the body’s T cells become “tired” following chemotherapy. JQ1 was recently employed as an investigational medication by University of Pennsylvania researchers to suppress the BET protein, enhancing the capabilities of CAR-T cells. Kong et al. shown how the BET protein can interfere with T cell CAR production and important acetylated histone activities in CLL patients [20].
TET2 methylcytosine dioxygenase levels are suppressed by BET protein inhibition, and increased BET protein targeting in CAR-T cells is eliminated by compelled expression of the TET2 catalytic domain. By focusing on two or more tumor-related chemicals, cancerous cells may be kept from escaping the immune system. Spiegel et al. assessed forty-four LBCL patients undergoing conventional CD19 CAR-T cell treatment. Of these, 89% had pretreatment cancer cells with significantly expressed CD19 on their surface. Among all LBCL patients, around half had progression of the disease [21].

Furthermore, at the time of relapse, 9 out of 15 (or 60%) had changed from CD19-positive to CD19-negative or low levels, indicating that these lymphoma cells may have eluded therapy [22].

**Figure 5: Advance developments with CAR-T cells**

Spiegel et al. also discovered that patients were more likely to respond favorably to treatment if they had more than about 3000 CD19 molecules per cancer cell surface, whereas patients with less CD19 individuals are more likely to experience a recurrence following an effective course of therapy [23].

**CAR-T CELL COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR**

The existence of immunosuppressive TME is one of the issues with CAR T cell treatment in solid malignancies, as was previously highlighted. This immunosuppressive microenvironment is the result of several causes, includes inhibiting substances like PD-1, CTLA-4, LAG-3, etc. One the other hand, the FDA has approved the use of monoclonal antibodies as an immunotherapy targeting these molecules (immune checkpoint inhibition), which has demonstrated potent anti cancer benefits [24]. However, recent research have demonstrated that the efficacy of CAR T cell treatment can be significantly increased by combining these ICBs with CAR T cells.

Antibodies like these can keep CAR T cells from becoming exhausted and enable them to continue acting as effectors [25].

**CONCLUSION**

Self-reproducing cells called CAR-T cells have advanced the treatment of cancer in notable ways. One example of how basic research is being applied to clinical practice is the development of CAR T cell therapy.

In general, the ability of CAR-T cells to be produced efficiently and delivered safely determines their use for cancer treatment. In general, the ability of CAR-T cells to be produced efficiently and delivered safely determines their use as cancer treatment.

Significant progress in the management of toxicity associated with CAR-T cell treatment might be achieved by better understanding the toxicity mechanism. The primary objective of CAR therapy is to explore its potential in nonhematological cancers, despite the fact that it has demonstrated notable efficacy in hematological malignancies. It appears that new approaches to immunotherapy will be necessary to get over the numerous challenges that CAR-T cell treatment in solid tumors must overcome. In the treatment of solid tumors, anti-tumor medications such as immune checkpoint inhibitors, radiation, chemotherapy, and oncolytic viruses may be used in combination with CAR-T cell therapy. Nevertheless, it does not appear to be easy to choose which oncolytic viruses are suitable for use in combination with CAR therapy given the wide range of viruses that are now accessible. Generally speaking, CAR success rates differ according on the kind of cancer. But since this kind of immunotherapy is still relatively new, there is still a lot to learn about its effectiveness.
ACKNOWLEDGEMENT:
The Authors of the article are thankful to the principal Dr. A Lakshmana Rao from V.V.Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, near Railway Station, Gudlavalleru, India for providing necessary facilities to publish this review article.

Conflict of Interest
The authors declare no conflict of interest, financial or otherwise.

Funding Support
The authors declare that they have no funding for this study.

REFERENCES


Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial- Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.